Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD

BACKGROUND AND OBJECTIVE: Neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody (MOG-IgG) associated disease (MOGAD) are autoimmune inflammatory demyelinating diseases of the central nervous system (CNS). As the clinical features of NMOSD are similar to MOG...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Liuyu, Wu, Yuqing, Hang, Hailun, Lu, Jie, Ding, Yuanliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309329/
https://www.ncbi.nlm.nih.gov/pubmed/35898513
http://dx.doi.org/10.3389/fimmu.2022.853891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309329/
https://www.ncbi.nlm.nih.gov/pubmed/35898513
http://dx.doi.org/10.3389/fimmu.2022.853891

Ejemplares similares